While world’s governments are making emergency provisions to prevent nasty variants of Covid-19 from decimating India (see here), Immunome, Inc. (IMNM) just asserted itself as a major defense against the threat of mutational drift.

This morning, the company announced the components of its novel B-cell antibody cocktail.

Here’s what immediately stands out and matters…

1. Serious Defense Against Variants

Remember, every vaccine in use today – and the most promising one being developed by Novavax, Inc. (NVAX) – only target a single spike protein. That means they’re increasingly less effective in treating mutations of the virus.

Not Immunome, though.


This content is reserved for subscribers. For a limited time only you can use Coupon Code NEWYEAR to receive $395 off an annual subscription. Click here to subscribe.